A real-world study (377) investigated the efficacy, safety, and cardio-renal outcomes of SGLT2i and GLP-1RA in 2.184 individuals with T1D treated with these agents together with insulin for at least 6 months. Here, INS is linked to type 1 diabetes mellitus.